Litigation Details for In Re: Humira (Adalimumab) Antitrust Litigation (N.D. Ill. 2019)

In Re: Humira (Adalimumab) Antitrust Litigation (N.D. Ill. 2019)

Docket		Date Filed	2019-03-18
Court	District Court, N.D. Illinois	Date Terminated	2020-06-30
Cause	15:1 Antitrust Litigation	Assigned To	Manish Suresh Shah
Jury Demand	Both	Referred To
Parties	LOUISIANA HEALTH SERVICE & INDEMNITY COMPANY D/B/A BLUE CROSS BLUE SHIELD OF LOUISIANA
Patents	7,820,799; 8,093,045; 8,663,945; 8,911,964; 8,926,975; 8,961,973; 8,986,693; 9,018,361; 9,067,992; 9,085,619; 9,090,689; 9,090,867; 9,096,666; 9,187,559; 9,255,143; 9,266,949; 9,359,434; 9,365,645; 9,512,216
Attorneys	Robin Van Der Meulen
Firms	Fine, Kaplan and Black
Link to Docket	External link to docket

Details for In Re: Humira (Adalimumab) Antitrust Litigation (N.D. Ill. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-08-09	109	Amended Complaint	in light of U.S. Patent No. 5,429,746 and a publication of U.S. Patent No. 7,820,799. Although it does…second patent not patentably distinct from claims in a first patent.”19 57. Patent prosecutions…another of 20 patents or patent applications. 131. The patent applications and patents fall roughly…’044 patent, the ’322 patent, and the ’491 patent in the U.K. Yet, as it did with the ’656 patent, prior…of AbbVie’s use patents and found three patents invalid due to obviousness: U.S. Patent No. 8,889,135;	External link to document
2019-10-11	124		Office. Compl. at 41; id. ¶¶ 114-20 (U.S. Patent Nos. 8,093,045; 8,911,964; 9,090,867; and 9,018,361). But… the United States Patent Office has granted, dozens of U.S. patents. The Patent Office has recognized…AbbVie’s patents, several biosimilar companies challenged the patents by petitioning the Patent Trial and…included two overlapping patents, AbbVie sued Amgen for patent infringement on 10 patents, including one for…adalimumab patents, including patents that expire after 2023. If even a single valid patent claim would	External link to document